Proposed changes to the blood monitoring and prescribing requirements for clozapine
Submission to Medsafe, 8 September 2025
Resources /
Submissions /
-
Submissions
- Petition of Aly Cook
- Proposed changes to streamline and update ACC regulations
- Draft Professional Standards for Physician Associates
- Consultation on Developing a Specified Prescription Medicines List for Designated Paramedic Prescribers
- Review of the Exceptional Circumstances Framework
- Proposed changes to Special Authority criteria for empagliflozin, liraglutide, and dulaglutide
- Proposed updates to eligibility settings for publicly funded health services
- Proposed changes to the Cost or Treatment Regulations and Definitions Regulations
- Australian Medical Council’s draft accreditation standards
- Updating the Pharmaceutical Schedule
- Aged Care Ministerial Advisory Group
- MCNZ regulation of physician associates
- Draft guidance on the Privacy Code of Practices
- Proposed Arms Bill
- Funding of RSV Vaccine nirsevimab for pēpi and tamariki in Aotearoa
- MedSafe Medical Classifications Committee (MCC) 75th Meeting
- Changes to the Options for Investment list changes to the Options for Investment list
- Proposal to fund access to infliximab, etanercept, secukinumab and rituximab
- Pharmac proposal to fund another ADHD medicine to improve supply
- Funding Support for Mpox (Jynneos) Vaccine Delivery in General Practice
- Proposed amendment to Medicines Regulations to enable authorised vaccinators to administer adrenaline
- Designated pharmacist prescriber specified prescriptions medicines list
- Designated registered nurse prescriber specified prescription medicines list
- Information Privacy Principle 3A
- Funding criteria for HIV medications
- Nursing Council Scope of Practice
- Proposed National Model for Integrated Adult Palliative Care
- Proposed amendments to the designated registered nurse prescriber specified prescription medicines list
- Proposed amendments to the designated pharmacist prescriber specified prescription medicines list
- Using artificial intelligence (AI) in patient care
- Proposal to fund a new brand of methylphenidate for ADHD
- MCNZ draft statements on Cultural Competency and Cultural Safety, and Hauora Māori
- Ministry for Disabled Peoples New Zealand Disability Strategy for 2026-2030
- Proposal to fund ticagrelor for people after minor stroke or high-risk TIA
- Proposed changes to Special Authority renewal requirements
- Proposed classification of substances as controlled drugs
- Healthy Futures (Pae Ora) Amendment Bill
- Medical aspects of fitness to drive: a guide for health practitioners
- Collegial peer support and supervision framework
- MedSafe Medical Classifications Committee 74th Meeting
- Pharmac prescription changes
- COPD Guidelines 2025 update
- Draft Guidance on the Information Privacy Principle (IPP)3A notification requirements for the indirect collection of personal information
- Proposal to fully fund two liquid nutrition replacements for adults with Crohn’s disease
- Proposal to enter into a new supply agreement for the COVID-19 vaccine
- Proposal to change the regulatory and funding restrictions for stimulant treatments for ADHD
- Draft guidance on establishing and sustaining human milk banks
- Proposal to support access to budesonide with eformoterol inhalers
- Proposal to fund Ryzodeg
- Cremation regulations review
- Putting Patients First: Modernising health workforce regulation
- Proposal to fund Mirena and Jaydess IUDs on a Practitioner Supply Order
- Migrating potential patient safety risk: Omeprazole 40mg and Flecainide 100mg capsules
- Advanced Cardiac Life Support Requirements for PGY1 Interns
- Proposal to fund the contraceptive pill desogestrel
- Proposal to widen access to medicines for blood cancer, inflammatory bowel diseases, eczema and rheumatoid arthritis
- Safety measures for the use of puberty blockers
- MedSafe Medical Classifications Committee (MCC) 73rd Meeting
- Treaty Principles Bill submission
- Unlocking the potential of active ageing
- Extension of the provisional vocational assessment period
- Proposal to increase the period of supply limit from 3 to 12 months
- Proposal to fund β-hCG low sensitivity urine test kits
- Hauora Māori Strategy
- Proposal to fund lung treatments, breast cancer, chronic obstructive pulmonary disease (COPD), prevention of RSV
- Agenda of Medicines Classification Committee meeting
- Strategy to Prevent and Minimise Gambling Harm
- Amendments to the Smokefree Environments and Regulated Products Act
- Proposal to remove the renewal criteria for stimulant treatments
- Proposal to fund lisdexamfetamine for ADHD
- Land Transport (Drug Driving) Amendment Bill
- Proposal to allow pharmacists to provide paracetamol to children under 2 years of age receiving the Bexsero vaccine
- Proposal to enable many childhood vaccinations to be given in pharmacies
- Emergency Management Bill
- Inquiry into Climate Adaptation
- Ministry of Health Precision Health
- Cost of Treatment Regulations
- Women’s Health Strategy
- The Therapeutic Products Bill
- Class B drug legislation
- Smokefree Environments and Regulated Products
- PASE whitepaper: more than a disease-based model
- Diabetes Action Plan 2022-2027
- National Screening Programmes, Breast Screen Aotearoa Service Standards
- Proposal to fund two brands of oestradiol patches
- Health and privacy information
- Proposed changes to the blood monitoring and prescribing requirements for clozapine
Also in this category
Submissions
Proposed changes to streamline and update ACC regulations
Submission to Ministry of Business, Innovation & Employment.
View resource